---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-024969"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T08:09:00.835079+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Unicycive reports 2022 net loss of $18.1M, cash $0.5M; closes $30M fundraise; NDA on track for mid-2023

## Summary
- Net loss for 2022 was $18.1M ($1.20/sh) vs $10.0M ($0.86/sh) in 2021.
- Cash and equivalents $0.5M at Dec 31, 2022; closed $30M private placement with up to $130M total.
- Renazorb pivotal BE study met primary endpoint; NDA submission on track for mid-2023.
- Exclusive license with Lotus Pharma for Renazorb in South Korea.
- R&D expenses $12.4M (up 103% YoY) driven by $6.5M in development services.

## SEC filing metadata
- accession: 0001213900-23-024969
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390023024969/0001213900-23-024969-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390023024969/ea176065-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-024969
- JSON: https://secwatch.observer/filing/0001213900-23-024969.json
- Plain text: https://secwatch.observer/filing/0001213900-23-024969.txt

## Key facts
- Earnings Releases
  Unicycive Therapeutics, Inc. reported financial results for full year ended December 31, 2022.
  - Period: full year ended December 31, 2022
  - Result: reported results
  source text: On March 31, 2023, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the full year ended December 31, 2022 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390023024969/0001213900-23-024969-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.